The Engineering Research Center for Revolutionizing Metallic Biomaterials (ERC-RMB) will be collaborating with Texas-based laboratory InCube Labs for the development and commercialization of medical and scientific research as part of a new agreement.
The National Science Foundation-funded ERC-RMB is led by institutions like the North Carolina-based NC Agricultural and Technical State University. Several other institutions, such as the University of Cincinnati, University of Pittsburgh (Pitt), and Hannover Medical School in Germany also support and collaborate on research and development programs at ERC-RMB. The Engineering Research Center strives to develop and design bioresearchable alloys of metals that can be used in the implantable therapeutic devices.
CEO and Chairman of InCube Labs, Mir Imran commented:
“Through our strategic relationship with Pitt and its Coulter Translational Research Partnership program, we became engaged with the ERC-RMB. We have been very impressed with the team, the facilities and capabilities that Dr. Sankar has assembled, and we look forward to a long term relationship that accelerates the pace of innovation, and delivers more effective solutions to patients. We are particularly excited about evaluating the biomaterials that the ERC-RMB is pioneering for commercial applications. We believe these innovations could lead to important clinical solutions that would dramatically improve patient outcomes.”
Essentials of the agreement:
According to the agreement, InCube will evaluate the potential applications and clinical uses of novel biomaterials that are commercialized or developed at the Engineering Research Center. ERC-RMB’s team is comprised of engineers and scientists who believe in the company’s vision to make advancements in bioresorbable metallic technology to improve the quality of life in patients suffering from chronic health issues.
Director of ERC, Dr. Jag Sankar, a professor of Mechanical Engineering at North Carolina Agricultural and Technical State University, explained:
“Our next step now is to work with industry to bring these innovations to market and to patients. InCube Labs has a tremendous track record of success in developing and commercializing breakthrough technologies, and we are thrilled with this relationship with InCube to advance our novel biomaterials to the next phase of development.”
Former Chair at the Bioengineering Department at University of Pittsburgh (Pitt), Dr. Harvey Borovetz, also expressed Pitt’s commitment to extending the cooperation and collaboration with ERC in order to promote further development in academia and technology: “Our relationship and agreement with InCube will help us harness scientific discoveries and translate them into commercial products that will ultimately improve healthcare.”
Through their new agreement, InCube is now connected to an extensive network of renowned universities and institutions to provide commercial and intellectual training to entrepreneurs and scientists within the biotech sphere.
About InCube Labs:
InCube Labs is based in San Antonio, TX and San Jose, CA. Since its inception, the lab strives to improve the quality of life of patients by promoting medical development and scientific innovation. Holder of over 200 patents and successful lead behind 20 life sciences institutions, InCube is another successful project of Mir Imran, inventor of the first Automatic Cardioverter Defibrillator approved by the FDA.